Testing information for clinicians
Products & Pipeline
Recent data now indicates that changing estrogen levels, specifically estrogen withdrawal, can trigger cancer in women with the KRAS-variant. Knowing a woman’s KRAS-variant status is an additional piece of critically important information to help direct decisions for estrogen management, as well as primary and secondary cancer screening.
This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment. Patients with any type of cancer who are being considered for this therapy are eligible for testing.
MiraDx has a program to confirm a diagnosis of Ataxia Telangiectasia in children, based on work from the Gatti laboratory spanning over 40 years.